BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anwar DM, El-Sayed M, Reda A, Fang JY, Khattab SN, Elzoghby AO. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes. Expert Opin Drug Deliv 2021;:1-17. [PMID: 34254868 DOI: 10.1080/17425247.2021.1955853] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Bai Z, Zhao L, Feng H, Xu H, Zhang N, Li Y, Song J, Bai Y, Yang R, Feng F. Fabricating Aptamer-functionalized Ti3C2 therapeutic nanoplatform for targeted chemo-photothermal therapy of cancer. Materials & Design 2023. [DOI: 10.1016/j.matdes.2023.111656] [Reference Citation Analysis]
2 Metawea MR, Abdelrazek HMA, El-hak HNG, Moghazee MM, Marie O. Comparative Effects of Curcumin versus Nano-Curcumin on histological, immunohistochemical expression, histomorphometric, and biochemical changes to pancreatic beta-cells and lipid profile of Streptozocin induced diabetes.. [DOI: 10.21203/rs.3.rs-2273377/v1] [Reference Citation Analysis]
3 Su Y, Zhang S, Li H, Zhao B, Tian K, Zou Z. Dimethylaminoethyl Methacrylate/Diethylene Glycol Dimethacrylate Grafted onto Folate-Esterified Bagasse Xylan/Andrographolide Composite Nanoderivative: Synthesis, Molecular Docking and Biological Activity. Molecules 2022;27:5970. [DOI: 10.3390/molecules27185970] [Reference Citation Analysis]
4 Chaturvedi S, Garg A. A comprehensive review on novel delivery approaches for exemestane. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.103655] [Reference Citation Analysis]
5 Asadollahi L, Mahoutforoush A, Dorreyatim SS, Soltanfam T, Paiva-Santos AC, Peixoto D, Veiga F, Hamishehkar H, Zeinali M, Abbaspour-Ravasjani S. Co-Delivery of Erlotinib and Resveratrol via Nanostructured Lipid Carriers: A Synergistically Promising Approach for Cell Proliferation Prevention and ROS-Mediated Apoptosis Activation. Int J Pharm 2022;:122027. [PMID: 35850183 DOI: 10.1016/j.ijpharm.2022.122027] [Reference Citation Analysis]
6 Zhou M, Zou X, Cheng K, Zhong S, Su Y, Wu T, Tao Y, Cong L, Yan B, Jiang Y. The role of cell-penetrating peptides in potential anti-cancer therapy. Clin Transl Med 2022;12:e822. [PMID: 35593206 DOI: 10.1002/ctm2.822] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
7 Chavda VP, Patel AB, Mistry KJ, Suthar SF, Wu ZX, Chen ZS, Hou K. Nano-Drug Delivery Systems Entrapping Natural Bioactive Compounds for Cancer: Recent Progress and Future Challenges. Front Oncol 2022;12:867655. [PMID: 35425710 DOI: 10.3389/fonc.2022.867655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
8 Zhang L, Liang B, Xu H, Gong Y, Hu W, Jin Z, Wu X, Chen X, Li M, Shi L, Shi Y, Wang Y, Yang L. Cinobufagin induces FOXO1-regulated apoptosis, proliferation, migration, and invasion by inhibiting G9a in non-small-cell lung cancer A549 cells. J Ethnopharmacol 2022;:115095. [PMID: 35176466 DOI: 10.1016/j.jep.2022.115095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Raza F, Zafar H, Khan MW, Ullah A, Khan AU, Baseer A, Fareed R, Sohail M. Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy. Mater Adv . [DOI: 10.1039/d1ma00961c] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
10 Zhang LX, Li CX, Kakar MU, Khan MS, Wu PF, Amir RM, Dai DF, Naveed M, Li QY, Saeed M, Shen JQ, Rajput SA, Li JH. Resveratrol (RV): A pharmacological review and call for further research. Biomed Pharmacother 2021;143:112164. [PMID: 34649335 DOI: 10.1016/j.biopha.2021.112164] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]